The case for & against
Bull & Bear analysis
Bearish
Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS). The company utilizes its proprietary Neuron platform aimed at addressing unmet medical needs in ALS, navigating complex regulatory landscapes to secure critical FDA approvals and partnerships. As Brainstorm positions itself within the promising, albeit challenging, biotech sector, it strives to leverage its unique technology to offer sustainable solutions for patients faced with limited treatment options.
Bull says
- ↑FDA SPA reduces Phase 3B Neuron trial regulatory risk.
- ↑Analysts trim model upsides, signaling optimistic earnings trajectory.
- ↑$15M grant and other non-dilutive sources limit shareholder dilution.
- ↑Strong patient advocacy engagement may accelerate trial enrollment.
- ↑Exosome platform expands pipeline into other neurodegenerative diseases.
- ↑High growth momentum and efficient leverage support scaling.
Bear says
- ↓2024 net loss of $11.6M underscores profitability challenges.
- ↓Only $0.4M cash as of year-end threatens trial financing.
- ↓BLA withdrawal and advisory feedback signal regulatory delays.
- ↓OTCQB listing shift and NASDAQ non-compliance dent investor confidence.
- ↓Volatile stock performance and slim margins heighten downside risks.
- ↓Trial initiation hinges on fresh capital, risking execution delays.
Earnings Call · Q3 2023 · Mgmt. Guidance
Updated 09-07-2026neutral
Transcript signals
Bull points
- We believe that having a SPA in place will de-risk the regulatory aspect of our ALS programs.
- We expect to raise money for the trial in stages. We also do not intend to wait to start the trial until we have raised the full amount needed.
- FDA is discussing with us an expedited pathway for a SPA. So that's just an additional answer to your question. What we're looking for expedited SPAs, you know, that if those companies that are able to have a SPA with FDA, there's a far higher chance for an approval at the end of the day.
Bear points
- we made the decision to withdraw the BLA for Neuron from FDA review. This decision was made following the outcome of the advisory committee that took place to review Neuron in September.
- are giving serious thought to how to finance the company and ensure we have the resources to fund the planned safety trial and position ourselves for success in the future.
- the strategic realignment will cut total resource consumption by approximately 50%. Many of us, including all senior management, took a 50% cut in their wages. As for myself, I took over a 90% cut from now.
Read full transcript analysis ›